Latest Breaking News On - Dana cormack - Page 6 : comparemela.com

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNEtm Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNEtm Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesOlivier danosAravindhan veerapandiyanChris brinzeyDana cormackWorld muscle societyTechnology platform licenseesCorporate communicationsSecurities exchangeClinical program updatesTechnology platformExchange commissionInternational congressManufacturing innovation centerInterim clinical dataAnnual international congress

REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society

/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 28th Annual Congress of the World Muscle Society, taking place in.

United statesJahannaz dastgirChris brinzeyDana cormackAravindhan veerapandiyanClinical developmentTechnology platform licenseesCorporate communicationsWorld muscle societyTechnology platformAnnual congressSenior directorArkansas childrenPlatform licenseesRegenxbio inc

REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome

RMAT recognizes that the preliminary clinical evidence from RGX-121, a potential one-time AAV Therapeutic, indicates the potential to address unmet medical needs for MPS II RMAT designation is for. | May 23, 2023

Dana cormackJoseph muenzerTerri kleinSteve pakolaChris brinzeyTechnology platform licenseesTreatment centerUniversity of north carolina at chapel hillTechnology platformCorporate communicationsManufacturing innovation centerDrug administrationInnovation centerBiologics license applicationRegenerative medicine advanced therapyMucopolysaccharidosis type

REGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023

ROCKVILLE, Md., May 22, 2023 /PRNewswire/ REGENXBIO Inc. today announced that it will present in a fireside chat and panel as well as host one-on-one investor meetings at the Barclays Gene. | May 22, 2023

Chris brinzeyDana cormackTechnology platformCorporate communicationsTechnology platform licenseesBarclays gene editingTherapy summitGene editingGenomic medicinesAre we readyPlatform licenseesRegenxbio inc stock exchangePress releaseArclays rgnx us75901b1070

REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium s First Rare Disease Clinical Portfolio

Research in MPS IVA led by REGENXBIO scientists moving into clinicDonation of NAV® Technology licenses will support development of gene therapies for rare diseasesROCKVILLE, Md., May 16, 2023. | May 16, 2023

Chris brinzeyDana cormackTechnology platform licenseesTechnology platformCorporate communicationsBespoke gene therapy consortiumNational institutesHealth accelerating medicines partnershipNemours childrenPlatform licenseesRegenxbio inc stock exchangePress releaseAy rgnx us75901b1070